Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche signs pharmacogenomics pact with Lilly

This article was originally published in Clinica

Executive Summary

Roche Diagnostics - under its business unit Roche Molecular Diagnostics - is collaborating with Eli Lilly to develop pharmacogenomics tests that may identify which patients will benefit most from certain cancer drugs. The Basel, Switzerland firm said that the agreement will initially focus on identifying biomarkers thought to influence patients' survival response rates to Lilly's anti-cancer therapies, pemetrexed (Alimta) and gemcitabine (Gemzar). Roche Molecular Diagnostics will develop any resulting companion diagnostic. Both companies will work with genetic profiling company Response Genetics, based in Los Angeles, California.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel